CN103694156B - 一种银屑病治疗药物钙泊三醇的制备方法 - Google Patents
一种银屑病治疗药物钙泊三醇的制备方法 Download PDFInfo
- Publication number
- CN103694156B CN103694156B CN201410007101.1A CN201410007101A CN103694156B CN 103694156 B CN103694156 B CN 103694156B CN 201410007101 A CN201410007101 A CN 201410007101A CN 103694156 B CN103694156 B CN 103694156B
- Authority
- CN
- China
- Prior art keywords
- calcipotriol
- preparation
- alcohol
- curing psoriasis
- tetraene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 title claims abstract description 20
- 229960002882 calcipotriol Drugs 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 201000004681 Psoriasis Diseases 0.000 title claims abstract description 8
- 239000003814 drug Substances 0.000 title claims abstract description 8
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 claims abstract description 10
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 239000001301 oxygen Substances 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 9
- 238000010511 deprotection reaction Methods 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 239000002904 solvent Substances 0.000 claims abstract description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 6
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000002635 aromatic organic solvent Substances 0.000 claims description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000001953 recrystallisation Methods 0.000 claims description 4
- 238000010792 warming Methods 0.000 claims description 4
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 2
- 238000006555 catalytic reaction Methods 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 229960001866 silicon dioxide Drugs 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 5
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000000047 product Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 238000005286 illumination Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 238000006552 photochemical reaction Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940075049 dovonex Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410007101.1A CN103694156B (zh) | 2014-01-07 | 2014-01-07 | 一种银屑病治疗药物钙泊三醇的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410007101.1A CN103694156B (zh) | 2014-01-07 | 2014-01-07 | 一种银屑病治疗药物钙泊三醇的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103694156A CN103694156A (zh) | 2014-04-02 |
CN103694156B true CN103694156B (zh) | 2015-09-02 |
Family
ID=50355848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410007101.1A Expired - Fee Related CN103694156B (zh) | 2014-01-07 | 2014-01-07 | 一种银屑病治疗药物钙泊三醇的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103694156B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105753758B (zh) * | 2014-12-17 | 2017-11-03 | 上虞京新药业有限公司 | 卡泊三醇的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4866048A (en) * | 1985-08-02 | 1989-09-12 | Leo Pharmaceutical Products Ltd. | Novel vitamin D analogues |
WO2003106412A1 (en) * | 2002-06-13 | 2003-12-24 | Teva Pharmaceutical Industries Ltd. | Epimerization of analogs of vitamin d |
CN1639329A (zh) * | 2002-01-10 | 2005-07-13 | 特瓦制药工业有限公司 | 差向异构的维生素d类似物的选择性酶促酯化和溶剂解以及所述差向异构体的分离 |
CN101400649A (zh) * | 2006-03-17 | 2009-04-01 | 利奥制药有限公司 | 药物中间体的异构化 |
WO2009057136A2 (en) * | 2007-08-03 | 2009-05-07 | Glenmark Generics Limited | Epimerization by stereoselective synthesis of vitamin d analogues |
CN101870708A (zh) * | 2009-04-21 | 2010-10-27 | 浙江京新药业股份有限公司 | 一种维生素d2衍生物的制备方法 |
-
2014
- 2014-01-07 CN CN201410007101.1A patent/CN103694156B/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4866048A (en) * | 1985-08-02 | 1989-09-12 | Leo Pharmaceutical Products Ltd. | Novel vitamin D analogues |
CN1639329A (zh) * | 2002-01-10 | 2005-07-13 | 特瓦制药工业有限公司 | 差向异构的维生素d类似物的选择性酶促酯化和溶剂解以及所述差向异构体的分离 |
WO2003106412A1 (en) * | 2002-06-13 | 2003-12-24 | Teva Pharmaceutical Industries Ltd. | Epimerization of analogs of vitamin d |
CN101400649A (zh) * | 2006-03-17 | 2009-04-01 | 利奥制药有限公司 | 药物中间体的异构化 |
WO2009057136A2 (en) * | 2007-08-03 | 2009-05-07 | Glenmark Generics Limited | Epimerization by stereoselective synthesis of vitamin d analogues |
CN101870708A (zh) * | 2009-04-21 | 2010-10-27 | 浙江京新药业股份有限公司 | 一种维生素d2衍生物的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103694156A (zh) | 2014-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103694156B (zh) | 一种银屑病治疗药物钙泊三醇的制备方法 | |
CN103570510A (zh) | 5-溴-2-氯-4’-乙氧基二苯甲烷的一锅合成方法 | |
CN103694306A (zh) | 一种布地奈德s异构体制备r异构体的方法 | |
CN102453011A (zh) | 一种高纯度柚皮素的制备方法 | |
CN102126911B (zh) | 一种高效生产番茄红素晶体的工业化方法 | |
CN114478340B (zh) | 一种提高维生素d3的原料利用率和产品收率的方法 | |
CN111116442A (zh) | 一种维生素d的制备方法 | |
CN109721496B (zh) | 一种3-硝基邻二甲苯的合成方法 | |
US20120108554A1 (en) | PROCESS FOR PREPARING HIGH PURITY 1alpha-HYDROXY VITAMIN D2 | |
CN102557980A (zh) | 结晶制备高纯辣椒碱单体的方法 | |
CN114716361B (zh) | 一种合成手性螺环茚酮-吡咯类化合物的方法 | |
CN105175355B (zh) | 一种2-氰基吩噻嗪的制备方法 | |
CN111269149B (zh) | 一种5-(3,3-二甲基胍基)-2-氧代戊酸的生产工艺 | |
CN102286004A (zh) | 拉氧头孢钠中间体的制备方法 | |
CN114409579B (zh) | 一种利用维生素d3副产物提高维生素d3收率的方法 | |
CN111233796A (zh) | 一种2,5-呋喃二甲醇的制备方法 | |
CN111925310A (zh) | 一种3-胺基-4-芳硒基马来酰亚胺化合物及制备方法 | |
CN117624004A (zh) | 一种制备骨化三醇的方法 | |
CN105085513A (zh) | 一种制备(r)-3-奎宁环醇的方法 | |
CN113956258B (zh) | 一种采用酸性离子液体的吲哚并[2,3-a]咔唑的制备方法 | |
CN103896903A (zh) | 制备和纯化2,3-o-异亚丙基苏糖醇的方法 | |
CN115872887B (zh) | 一种阿戈美拉汀的制备方法 | |
CN108752408B (zh) | 从微生物法制备雄烯二酮的固体下脚料中回收、精制雄烯二酮的方法 | |
CN111377894B (zh) | 一种3-n-丁基-l(3H)-异苯并呋喃酮的纯化方法 | |
CN102633853B (zh) | 一种从混合植物甾醇中提纯菜油甾醇的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170518 Address after: 610041, Sichuan, Chengdu province Wuhou District 9 Bridge Street wash two district Patentee after: Chengdu Jingqin Excellent Drug Development Co.,Ltd. Address before: Science Park high tech Zone of Chengdu South Road, No. 88 610041 Sichuan province Tianfu Life Science Park building B6 No. 9 Patentee before: CHENGDU YILUKANG MEDICAL TECHNOLOGY & SERVICE Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180309 Address after: 610000 floor, building B6, Tianfu Life Science & Technology Park, No. 88, South Park Road, high tech Zone, Sichuan, Chengdu, China Patentee after: CHENGDU YILUKANG MEDICAL TECHNOLOGY & SERVICE Co.,Ltd. Address before: 610041, Sichuan, Chengdu province Wuhou District 9 Bridge Street wash two district Patentee before: Chengdu Jingqin Excellent Drug Development Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150902 |